Daiichi Sankyo takes up flu drug for Japan
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo has formally taken up an option to manufacture and market in Japan the inhaled long-acting neuraminidase inhibitor and potential Tamiflu competitor CS-8958.